Evolution of copro-tests in active detection of colorectal cancer
Abstract
The aim of review. To present state-of-the-art in active detection of risk group for colorectal cancer (CRC) by screening laboratory methods – biochemical and immunoenzyme.
Key points. The high morbidity and a mortality in the world from CRC makes active detection of this disease very important, thus the first stage of investigation supposes application of non-invasive laboratory methods. It was demonstrated, that biochemical methods for fecal occult blood testing (hemoccult tests) – guaiac Weber's test (gFOBT) and Gregersen test, at adherence to rules of procedure technique, are applicable for active detection of CRC and some other gastro-intestinal diseases. However, low specificity of biochemical tests and necessity of long preparation for analysis limit their clinical application. Searches of the laboratory methods, that allow to overcome this restriction, resulted in development several qualitative (rapid) and quantitative enzyme-linked immunoassays for detection of hemoglobin in feces (FIT). Essential difference of immunoenzyme tests from biochemical is application of antibodies, specific to human hemoglobin and complex of human hemoglobin with haptoglobin. These tests are deprived of some disadvantages of biochemical method. Besides that, detection of the tumor-specific pyruvate kinase type М2 in feces (fTu M2-PK) also can be used in the screening programs for active detection of CRC, as it was shown in series of studies.
Conclusion. Now series of copro-tests are available, that are promising for application as screening laboratory methods for active detection of high risk groups for CRC.
About the Authors
V. I. ChissovRussian Federation
N. S. Sergeyeva
Russian Federation
Ye. V. Zenkina
Russian Federation
N. V. Marshrutina
Russian Federation
References
1. Бейсембаева Р.У. Гаптоглобин и его клиническое значение // Клин. мед. – 1986. – № 1. – С. 13–15.
2. Гиршберг Л. Техника исследования и клиническое значение скрытой крови в испражнениях // Врач. газета. – 1922. – № 9.
3. Кулибакин Б.В. Большая медицинская энциклопедия. – 1976. – Изд. 3-е / Под ред. Б.В. Петровского. – Т. 3. – С. 38.
4. Кулибакин Б.В. Там же. – Т. 5. – С. 68.
5. Мовшович Б.Л., Русаков В.М. Исследование сывороточного гаптоглобина и внеэритроцитарного гемоглобина при некрозах миокарда // Кардиология. – 1972. – № 5. – С. 116.
6. Состояние онкологической помощи населению России в 2008 г. / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. – М., 2009. – 190 с.
7. Степанов Б.И. Большая медицинская энциклопедия, 1976. – Изд. 3-е / Под ред. Б.В. Петровского. – Т. 8. – С. 446.
8. Тимофеев Ю.М. Колоректальный рак: современные аспекты диагностики и лечения // РМЖ. Независ. изд. практ. вр. – 2004. – Т. 12, № 11. – С. 653–656. – http://www.rmj.ru/articles_304.htm.
9. Тиц Н.У. Энциклопедия клинических лабораторных тестов. – М.: Лабинформ, 1997. – 942 с.
10. Трифонов Е.В. Психофизиология человека // Русскоангло-русская энциклопедия. – 2009. – 13-е изд. – http://www.tryphonov.ru/ tryphonov1/terms1/ideal. htm.
11. Чиссов В.И., Дарьялова С.Л. Онкология: учебник. – 2007. – 560 с.
12. Энциклопедический словарь по судебной медицине и смежным проблемам /Под. ред. Корсакова С.А. – Gag.htm.
13. Allison J.E. et al. Comparing fecal immunochemical tests: improved standardization is needed // Gastroenterology. – 2012. – Vol. 142. – P. 422–424.
14. Atkinson D.E., Walton C.M. Adenosine triphosphate conservation in metabolic regulation // J. Biol. Chem. – 1967. – Vol. 10. – P. 3239–3241.
15. Bertario L. Reducing colorectal cancer mortality by repeated faecaloccult blood test a nested case–control study // Eur. J. Cancer. – 1999. – Vol. 35. – P. 973– 977.
16. Bilgrami G., Tyagi S.P., Qasum A. Serum haptoglobin in cases of ischemic heart diseases // Jpn. Heart J. – 1980. – Vol. 21, N 4. – P. 505–510.
17. Bresaller R.S. Blood-Based Biomarcers: Key Concepts in development and Clinical validation for CRC in Population screening // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
18. Burtonwood C. Monitoring faecal occult blood test positivity in the NHS Bowel Cancer Screening Programme // Ibid.
19. Chapelle J.P., Albert A., Smeets J.P. et. al. Effect of the haptoglobin phenotype on the size of a myocardial infarct // New Engl. J. Med. – 1982. – Vol. 307, N 8. – P. 457–463.
20. Church T.R. et al. Fecal occult blood screening in the Minnesota Study: Sensitivity of the screening test // J. Natl. Cancer Inst. – 1997. – Vol. 91. – P. 1440–1448.
21. Cole S.R. Cancer Downstaging As a Consequence of the Australian National Bowel Cancer Screening Program // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
22. Collins J.F., Lieberman D.A., Durbin T.E. et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice // Ann. Intern. Med. – 2005. – Vol. 142 (2). – P. 81–85.
23. Dekker E. How to deal with patients with a positive family history for CRC in population screening // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
24. De Vos T. Septin 9 DNA Methylation Biomarker for the Detection of Colorectal Cancer in Blood // Ibid.
25. Duffy M.J. Use of biomarkers in screening for cancer // Tumor Biol. – 2011. – Vol. 32 (suppl. 1). – P. 5–56; O16.4 (S49).
26. Ederer F. et al. Fecal occult blood screening in the Minnesota Study: Role of chance detection of lesions // J. Natl. Cancer Inst. – 1997. – Vol. 89. – P. 1423–1428.
27. Eigenbrodt E., Kallinowski F., Ott M. et al. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors // Anticancer Res. – 1998. – Vol. 18. – Р. 3267–3274.
28. Eigenbrodt E., Mazurek S., Friis R.R. Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools // Cell Growth and Oncogenesis. – 1998. – P. 15–30.
29. Ewald N., Shaller M., Bayer M. et al. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer // Anticancer Res. – 2007. – Vol. 27 (4A). – Р. 1949–1952.
30. Faivre J., Tazi M.A. Fecal occult blood screening ahd reduction of colorectal cancer mortality; a case control study // Br. J. Cancer. – 1999. – Vol. 79. – P. 680–683.
31. Fraser C.G., Matthew C.M., Mowat N.A. et al. Immunochemical testing of individuals positive for guaiac fecal occult blood test in a screening program for colorectal cancer: an observation study // Lancet Oncol. – 2006. – Vol. 7 (2). – P. 127–131.
32. Goodenowe D. Validation of Low Serum GTA-446 Levels for Identifying Subjects with High CRC Risk // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
33. Gregersen Т. Untersuchungen tiber okkulte Blutungen // Arch. f. Ver-dauungskrankheiten, B. XXV, 1919.
34. Halloran S., Launoy G., Zappa M. Faecal occult blood testing // European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. – 2010. – First Edition.
35. Halloran S., Pearson S. OC-Sensor DIANA immunochemical faecal occult blood test analytical performance // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
36. Hardcastle J.D. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer // Lancet. – 1996. – Vol. 348. – P. 1471–1477.
37. Hardt P.D., Toepler M., Ngoumou B. et al. Fecal pyruvate kinase (ELISA based on c combination of clone
38. and 3 antibodies) for gastric cancer // Anticancer Res. – 2003. – Vol. 23. – P. 851–854.
39. Haug U., Rothenbacher D., Wente M.N. et al. Tumor M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients // Br. J. Cancer. – 2007. – Vol. 7; 96 (9). – P. 1329–1334.
40. Hewitson P., Glasziou P.P., Irwig L. et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult // Cochrane Database of Systematic Reviews. – 2007. – Issue 1. – Art. No.: CD001216. DOI: 10.1002/14651858.CD001216.pub2. (Copyright © 2011 The Cochrane Collaboration Published by John Wiley & Sons, Ltd).
41. Hwang P.K., Greer J. // J. Biol. Chem. – 1980. – Vol. 255. – Р. 3038–3041.
42. Imperiale T.F. Molecular markers – are they ready yet? // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
43. Jayle M.F., Judas O. Formule glycoprotéidique du plasma sanguine // Helv. Chim. Acta. – 1946. – Vol. 29. – P. 1310–1314.
44. Johansson B.G., Kindmark C.O., Irele E.Y. et al. Sequential changes of plasma proteins after myocardial infarction // Scand. J. Clin. Lab. Invest. – 1972. – Vol. 124. – P. 117–126, 134–141.
45. Jover R. et al. Factors related with detection of adenomas in screening colonoscopy // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
46. Karl J., Wild N., Tacke M. et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markrs // Clin. Gastroenterol. Hepatol. – 2008. – Vol. 6 (10). – P. 1122–1128.
47. Koss K., Maxton D., Jankowski J.A. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention // Colorectal Dis. – 2008. – Vol. 10 (3). – P. 224–228.
48. Kronborg O. et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test // Lancet. – 1996. – Vol. 348. – Р. 1467–1471.
49. Kurosky A., Barnett D.R., Lee T.-H. et al. // Proc. Natl. Acad. Sci. U.S.A. – 1980. – Vol. 77. – P. 3388–3392.
50. Lange V. Haptoglobin polymorphism – Not only a genetic marker // Anthropol. – 1992. – Vol. 50. – P. 281–302.
51. Lustbader J.W., Arcoleo J.P. et al. Hemoglobin-binding site on haptoglobin probed by selective proteolysis // J. Biol. Chem. – 1983. – Vol. 258 (2). – Р. 1227–1234.
52. Mandel J.S. et al. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood
53. // J. Natl. Cancer Inst. – 1999. – Vol. 91. – Р. 434–437.
54. Mandel J.S. et al. Reducing mortality from colorectal cancer by screening for fecal occult blood // N. Engl. J. Med. – 1993. – Vol. 328. – Р. 1365–1371.
55. Matsuda T. The Characteristics of Interval Cancers and Right-sited Lesions from the Japanese Perspective // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
56. Mazurek S., Grimm H., Oehmke M. et al. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells // Anticancer Res. – 2000. – Vol. 20. – P. 5151–5154.
57. Meguro T. Measurement of fecal hemoglobin-haptoglobin complex as a new diagnostic tool of lower GIT diseases
58. // Hokkaido Igaku Zasshi. – 1994. – Vol. 69 (4). –P. 995–1009.
59. Melo R.F., Stevan F.R., Campello A.P. et al. Occurrence of the crabtree effect in Hela cells // Cell Biochem. Funct. – 1998. – Vol. 16. – Р. 99–105.
60. Oremek C.M., Teigelkamp S., Kramer W. et al. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma // Anticancer Res. –1999. – Vol. 19. – Р. 2599–2602.
61. Pohl H. Incomplete adenoma resection during colonoscopy. The Complete Adenoma Resection Study (CARE Study)// WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
62. Polonovski M., Jayle M.F. Existence dans le plasma sanguin d’une substance activant l’action peroxydasique, l’haptoglobine // C. R. Seances Soc. Biol. Fil. – 1938. – Vol. 129. – P. 457–460.
63. Prdersen S.K. et al. Discovery and validation of novel DNA methylation biomarkers for colorectal cancer with application to blood testing // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
64. Presek P., Reinacber M., Eigenbrodt E. Pyruvale kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus // FEBS Letters. – 1988. – Vol. 242. – P. 194–198.
65. Rex D.K. Serrated lesions, variable detection, pathologic interpretation and interobserver variation // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
66. Sanduleanu S. Incidence and potential explanations of interval cancers after colonoscopy // Ibid.
67. Schoen E.R. Interval Cancers in the PLCO Trial // Ibid.
68. Seig A., Thoms C., Lüthens K. et al. Detection of colorectal neoplasms by the highly sensitive hemoglobinhaptoglobin complex in feces // Int. J. Colorectal Dis. – 1999. – Vol. 14 (6). – P. 267–271.
69. Senore C. The burden for surveillance of population screening programs // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
70. Smithies O. Zone electrophoresis in starch gels: Group variations in the serum proteins of normal human adults // Biochemistry. – 1955. – Vol. 61. – P. 629–641.
71. Smithies O., Walker N.F. Notation for serum-protein groups and the genes controlling their inheritance // Nature. – 1956. – Vol. 178. – P. 694–695.
72. Tonus C., Neupert G., Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK // World J. Gastroenterol. – 2006. – Vol. 12 (43). – P. 7007–7011.
73. Toth K. et al. Plasma methylated Septin9 is a screening marker in both left and right-sided colon cancer. Comparison to FOBT and CEA results // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
74. Wang H. et al. A New And Highly Sensitive Screening Tool For Colorectal Adenomatous Polyps Using A Spot Urine Metabolomics Test // Ibid.
75. WGO Practice Guidelines. – 2008.
76. Zauber A.G. Adherence to Screening in a Randomized Controlled Trial of a One-Time Screening Colonoscopy versus Program of Annual Fecal Occult Blood Test (gFOBT): Implications of Lower gFOBT Adherence to Screening on Colorectal Cancer Mortality Reduction // WEO Colorectal Cancer Screening Committee Meeting, May 18, 2012.
Review
For citations:
Chissov V.I., Sergeyeva N.S., Zenkina Ye.V., Marshrutina N.V. Evolution of copro-tests in active detection of colorectal cancer. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2012;22(6):44-52. (In Russ.)
Views:
101
Email this article 
